NanoVibronix (NASDAQ: NAOV) Shares Key Insights from Annual Stockholder Meeting

NanoVibronix, Inc. recently presented crucial information from its Annual Meeting of Stockholders, held on December 19, 2024. The company’s Chief Executive Officer, Brian Murphy, shared pertinent details during the meeting. NanoVibronix, Inc. disclosed that Mr. Murphy’s presentation materials from the event are now available for review in Exhibit 99.1 of the current Form 8-K filing. The company highlighted that it assumes no responsibility to update or modify the information contained in these materials going forward.

As per the regulations outlined in Item 7.01, the details presented in this Form 8-K, along with the attached Exhibit 99.1, are being released, in compliance with the disclosure requirements. It is clarified that this information is not being filed for the provisions of Section 18 of the Securities Exchange Act of 1934. Additionally, it is not subject to the liabilities of that section, nor does it imply incorporation by reference in any filings under the Securities Act of 1933 or the Exchange Act.

For further financial transparency, NanoVibronix, Inc. also declared the inclusion of financial statements and specific exhibits as part of Item 9.01 of the filing. Exhibit 99.1 consists of the 2024 Annual Stockholder Meeting Presentation.

Finally, in compliance with the necessary legalities, the report has been officially signed by Stephen Brown, the Chief Financial Officer of NanoVibronix, Inc., on December 19, 2024. The completion of this report signifies the fulfillment of the Securities Exchange Act of 1934 requirements for the company.

This information is critical for stakeholders and investors to understand the recent developments and strategic directions as communicated by NanoVibronix, Inc. at its Annual Meeting of Stockholders.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read NanoVibronix’s 8K filing here.

NanoVibronix Company Profile

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.